ECONOMIC IMPACT OF CANCER CHEMOTHERAPY DRUG WASTAGE IN DAYCARE WARD IN A TERTIARY CARE HOSPITAL.

Author(s)

Gopisankar MG1, Wahlang J2, Jagtap V2, Sarkar C2, L. PD2, Harris C2
1Department of Pharmacology, Director's Block, Neigrihms, Mawdiangdiang, Shillong-793018, shillong, ML, India, 2NEIGRIHMS, shillong, India

OBJECTIVES: Assessing economic loss by cancer drug wastage in 3 months (October-December 2018) and retrospective analysis of drug usage in previous 3 months.

METHODS: Electronic balance (MAB220, Wenser®) was set up in the preparation room. Drugs for solid malignancies (liquid dosage form) were pre-weighed and post weighed to find drug remaining in vial. Estimated drug loss was assessed by finding difference between quantity in vial and dose required for patient. Actual drug loss was assessed by direct conversion of left-over drug in vials into money value.

RESULTS: Analysed 423 prescriptions over 6 months. Number of patients were 163 with 53% (n= 87) females. Mean (SD) age was 51(14) years. The mostly prescribed drugs were carboplatin (n=60, 37%), paclitaxel (n=57, 35.2%), oxaliplatin (n=34, 21%) and epirubicin (n=22, 13.6%) and diagnosis was carcinoma Stomach (16%). Total expenditure on drugs (6 months) was Rs.3981625 with median (IQR) cost per prescription was Rs.9000 (7131). Estimated total drug wastage costs Rs.759064 (6 months).The economic loss due to drug wastage was 19.06% of the total expenditure on drugs alone. Highest percentage of average loss per prescription was for pemetrexed (46.45%). Percentage of available vial strengths exactly matching the patient requirement was 87.9, 50, 47.8, 33.9, 26.8, 22.8,21.2, 20.0, 18.2,13.5, 13.3, 4.3, 3.6 for cisplatin, etoposide, irinotecan, gemcitabine, epirubicin, paclitaxel, doxorubicin, docetaxel, carboplatin, cyclophosphamide, oxaliplatin, 5FU and pemetrexed respectively. There was no significant difference between estimated drug wastage and quantitated drug wastage in three months (Rs.390951 vs. 393375, p=0.210)as well as for age ,(p=0.909) and gender (p=0.920) on the drug wastage.

CONCLUSIONS: There is significant drug wastage of chemotherapeutic agents in the day care setting. One-fifth of the expenditure on drugs is getting wasted. Exact vial strength is available only on an average of one-fourth of the prescriptions. There were no other significant variables related to drug wastage.

Conference/Value in Health Info

2019-05, ISPOR 2019, New Orleans, LA, USA

Value in Health, Volume 22, Issue S1 (2019 May)

Code

PCN121

Topic

Economic Evaluation, Health Policy & Regulatory

Topic Subcategory

Cost/Cost of Illness/Resource Use Studies, Pricing Policy & Schemes, Public Spending & National Health Expenditures, Work & Home Productivity - Indirect Costs

Disease

Drugs, Oncology, Personalized and Precision Medicine

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×